ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Study Section Members Likelier to Be Funded

August 1, 1986

Research community needs to be prepared for budget “flattening,” NCI director says.

March 25, 2005

Symptoms Don’t Help Detect Early-Stage Ovarian Cancer

February 26, 2010

AIDs Concepts Totaling $13 Million Approved By DCT Board; Will Be Funded By Special Appropriations

October 11, 1985

Suitable Mechanism, Funding Source Were Issues In diet FIT

December 15, 1989

NIH Consensus Conference Agenda, Registration Online.

September 1, 2000